A number of gene therapies are in late-stage clinical trials and expected to reach the market in the next several years.PAP-Q4-17-CL-002
Keeping up with quality is key for the industry throughout the supply chain. Quality must be ensured from the earliest phases of development.PAP-Q4-17-FA-001
The (bio)pharmaceutical industry is becoming a high-technology sector with success directly linked to innovation.PAP-Q4-17-NO-001
Lack of effective management of the outbound distribution of clinical trial materials can negatively impact study outcomes.PAP-Q4-17-CL-001
The contract manufacturing market for antibody-drug conjugates has huge potential, but an extraordinary range of capabilities is essential to be in the game.PAP-Q04-17-VP-001
Efficient development of optimal routes and manufacturing processes for the production of increasingly complex small molecule APIs requires extensive expertise.PAP-Q4-17-CL-003
Following a string of approvals, biosimilars are positioned to go the way of generics.PAP-Q4-17-FA-002
Call it the automation of everything — a hands-off approach will permeate supply chains in the near future.PAP-Q4-17-FA-003
Potassium channels are present in nearly all types of cells and involved in most physiological functions.PAP-Q4-17-CL-004
Reducing the time, cost and environmental footprint of manufacturing processes continues to be a major driver of technology development.PAP-Q3-17-CL-003
Single-use technologies (SUTs) have introduced a broad range of cost and operating efficiencies to bioprocessing operations.PAP-Q4-17-CL-006
Anticipating 2018 technologies and their impact.PAP-Q4-17-RT-002
Q: What do you see as being the most innovative technologies introduced in 2017? Why were they important? What impacts did they have?
The importance and impact on innovative technologies introduced in 2017.PAP-Q4-17-RT-001
Optimizing API Production as a True Manufacturing Partner
Jim Scandura, Executive Vice President, Chief Operating Officer at Avara Pharmaceutical Service discusses serving as a partner for API production.
Latest Developments in Cellular and Gene Therapies
Although numerous cellular and gene therapy products are currently in different phases of clinical trials, only 14 have been approved for use by FDA to date.
An OEE Approach To Solid Dose Equipment Purchasing and Implementation
Adam Covitt, Vice President of Federal Equipment Company discusses strategic equipment acquisition.
Keys to Cultural Integration
That’s Nice sat down with Catherine Hanley, Alcami’s Director of Marketing, to find out how to successfully integrate after a merger.
Continuous Processing: Meeting the Need for New Manufacturing Strategies
Filipe Gaspar, Vice President, R&D, Nuno Matos, Head of Continuous Manufacturing, R&D and Marco Gil, General Manager for Hovione discuss the paradigm shift in pharmaceutical production.
Equipment Must Integrate
Budgets for pharmaceutical equipment continue to increase.
Sebaceous Glands in 3D
BASF & CTIBiotech release bioprinting breakthrough.
Boehringer Ingelheim and Adimab Partner on Antibodies
BI will leverage Adimab’s platform to optimize antibodies against targets of their choice.
EU Approves AstraZeneca’s Respiratory Biologic
The European Commission (EC) approved the first-ever respiratory biologic with an 8-week maintenance dosing schedule.
Marken Opens New Kit Building Facility In Shanghai
New location combines kit building and clinical logistics to support China growth.
Moving Quality to the Forefront Brings Measurable Results
Chris Curtin, Executive Vice President and Chief Operating Officer of UPM Pharmaceuticals explains the implementation of Manufacturing Quality Assurance (MQA).
Embracing Formulation Expertise to Extend Exclusivity & Improve the Patient Experience
Syed T. Husain, Chief Commercial Officer at Alcami explains the value of reformulation efforts.
Achieving Large-Scale Cell and Gene Therapy Manufacturing
Mark Bamforth, Cofounder and CEO, Richard Snyder, Ph.D., Chief Scientific Officer and Steve Kasok, Chief Financial Officer and Cofounder at Brammer Bio discuss the commercialization of advanced treatments.
Quality by Design: Transforming 21st Century Pharmaceutical Manufacturing
John Moscariello, Ph.D., Vice President, Process Development at CMC Biologics discusses the QbD concept.
Disease-In-A-Dish: Leveraging in vitro Human Models to Advance Drug Discovery
Paul R. August, Vice President, and Mark J. Pincus, M.S., Senior Research Investigator, Translational Patient Cell Models at Icagen Inc., discuss the possibility of phasing out animal models.
Dry-Powder Inhalation Formulation: Balancing Performance and Manufacturability
Eunice Costa, Group Leader, Inhalation and Conrad Winters, Director Drug Product Development at Hovione explain composite particle technology.
Clinical Decision-support Software to be Developed by Roche and GE Healthcare
The two companies will look to improve individualized treatment of cancer and critical-care patients.
Impact Biomedicines Acquired By Celgene
Celgene to pay $1.1 billion upfront and up to $5.9 billion in milestone fees.
Takeda Moves into Stem-Cell Therapies with Acquisition of TiGenix
TiGenix agrees to $620-million voluntary public takeover bid from Takeda.
Abzena Continues to Expand Globally
The biopharma company is consolidating its research and administration capabilities in Cambridge, UK and San Diego, US.
Nice Insight Research
Chain Annual Study
- Transient Transfection at a Large Scale for Flexibility in Clinical and Commercial Vector Manufacturing Richard Snyder, Ph.D., Scott Jeffers, Ph.D, Ying Cai, Ph.D., Brammer Bio
- Supporting the Pharma Industry Small Business Growth Engine Syed T. Husain, Catherine Hanley, Alcami
- Experience and Expertise Facilitate Controlled Substance Manufacturing Kim Noll, Patrick Hatem, UPM Pharmaceuticals
- Achieving a High Level of Customer Service Through Lean Quality Management Warren Horton, Avara Pharmaceutical Services
- Russian Pharma Market Offers Great Potential for Local Manufacturers Renaud Bessière, Servier CDMO
- Mitigating Shortages of Injectable Drugs in the United States Marga Viñes, Grifols
- Enabling Right-First-Time Tech Transfer with Effective Scale-Down Modeling Erich Blatter, Ph.D., GSK Contract Manufacturing
Pharma's Almanac TVView All Video
Road To BIO: Coming Soon To Your Screen
That’s Nice is producing a film based on the Road To BIO, for release in 2017. Watch the teaser trailer to get a taster of all the behind-the-scenes stories, character insights, and what went into the project.
Facility Expansion at Abzena
John Manzello, President, US, Abzena
Attracting Investors and Shortening Development Times
James C. Greenwood, President & CEO, Biotechnology Innovation Organization (BIO)
Providing a Complete Modular Solution
George Wiker, Executive Director, AES
Bringing Bioscience to Space
Bill Goodman, Ph.D., Vice President, SCORPIO-V, a Division of HNu Photonics
Devin Ridgley, Project Scientist, SCORPIO-V, a Division of HNu Photonics
LatestView All Latest
Jan 16, 2018 2:28:55 PM PAO-M01-18-NI-028
Jan 16, 2018 1:08:30 PM PAO-M01-18-NI-026
Jan 12, 2018 2:00:15 PM PAO-M01-18-NI-024
Jan 12, 2018 1:05:06 PM PAO-M01-18-NI-023
Jan 11, 2018 2:36:49 PM PAO-M01-18-NI-020
Jan 11, 2018 2:28:58 PM PAO-M01-18-NI-018
TOPICSView All Topics
Jan 18, 2018 3:30:00 PM
Jan 18, 2018 7:55:00 AM
Jan 18, 2018 7:30:00 AM
Jan 17, 2018 7:50:00 AM
Jan 17, 2018 7:41:00 AM
Jan 17, 2018 7:40:00 AM
The contract manufacturing market for antibody-drug conjugates has huge potential, but an extraordinary range of capabilities is essential to be in the game. We spoke to some of the players to find out all about ADCs.
By the Numbers
2017 Top 5 Industry Leaders
Now stronger than ever, Marken needed a bold visual direction to illustrate its expanding breadth of services and ongoing commitment to personalized medicine.
Nice Insight Overview